Bevacizumab-Kamada (bevacizumab biosimilar) / Kamada - LARVOL DELTA

Kamada Announces Expansion of Biosimilars Portfolio with the Launch of Two Additional Products in Israel (The Manila Times) - "The two newly launched biosimilar products are Ustekinumab-Kamada, a biosimilar to Stelara, a monoclonal antibody indicated for the treatment of chronic immune-mediated inflammatory diseases, including plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis, and Enoxaparin-Kamada, a biosimilar to Clexane, a low-molecular-weight heparin indicated for the prevention and treatment of thromboembolic disorders, including deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as for use in certain acute coronary syndrome settings....The Company expects the commercial availability of at least two additional biosimilar products during 2027."

Biosimilar launch • Crohn's disease • Plaque Psoriasis • Psoriatic Arthritis • Pulmonary Embolism • Ulcerative Colitis • Venous Thromboembolism